Michael S. Poirier
CIK 1812504 · Chairman and CEO · last filed 2022-08-04
Michael S. Poirier is a Chairman and CEO who has filed 5 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for QLGN, was dated Aug 4, 2022. Across all open-market trades the lifetime net is +$36.9K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
5
$36.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Qualigen Therapeutics, Inc. (QLGN) Delisted | Chairman and CEO | 210,207 | $3.21 | $674.8K | $36.9K | 5 | 2022-08-04 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-04 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-22 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Buy (P) | +30,000 | $17.1K | EDGAR |
| 2021-04-21 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Buy (P) | +11,005 | $19.8K | EDGAR |
| 2020-06-08 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-27 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Other (J) | +169,192 | $0 | EDGAR |